Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential

2. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) 

Number of Hedge Fund Holders: 42

Upside Potential: 80.19%

The commercial-stage biotech company Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is developing a pipeline of RNA-targeted medications. Its marketed treatments include familial chylomicronemia syndrome, hereditary ATTR amyloidosis, and spinal muscular atrophy. With the recent launch of TRYNGOLZA and the development of a solid royalty base from partnered drugs like SPINRAZA and WAINUA, Ionis has made the shift to independent commercialization. Additionally, the company has extensive clinical-stage assets that address rare neurological illnesses, severe hypertriglyceridemia, and hereditary angioedema. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) represented about 0.58% of Glenn Russell Dubin’s portfolio.

Revenue for the quarter ending March 31, 2025, was $132 million, a 10% year-over-year increase, according to Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) earnings report. With an EPS of -$0.93 compared to the average of -$1.11, earnings exceeded expectations. WAINUA’s $9 million and SPINRAZA’s $48 million royalties helped non-GAAP operating losses drop by over 25% to less than $375 million. The company forecasted a strong year-end cash position of $1.9 billion and increased its full-year revenue outlook to $725–750 million.

During its first full quarter, Ionis’s first independently marketed treatment, TRYNGOLZA, generated over $6 million in revenue. With Olezarsen Phase III results anticipated in Q3 for a possible sNDA by year-end and Donidalorsen awaiting FDA approval in August 2025, pipeline progress remained robust. Ionis is also moving several neurology-focused therapies, such as ION582 and Zilganersen, closer to Phase III development.

Strategic partnerships with Biogen, GSK, and Sobi, as well as licensing income from deals like the $280 million sapablursen contract, support Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) projection of over $3 billion in peak yearly sales from its wholly owned medications. One of Glenn Russell Dubin’s best stock selections with significant upside potential is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).